AI assistant
IRONVELD PLC — Remuneration Information 2019
Oct 22, 2019
7719_rns_2019-10-22_468467b4-18c3-4e31-9c9c-076dd3c68efd.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 6187Q
Ironveld PLC
22 October 2019
Ironveld plc ("Ironveld" or the "Group")
Blocklisting Return
The Company gives below the information required by Schedule 6 of the AIM Rules for Companies in connection with the Ironveld plc Long Term Incentive Plan and EMI Share Option Scheme.
| Name of applicant: | Ironveld plc | |||
| Name of scheme: | Ironveld plc Long Term Incentive Plan and EMI Share Option Scheme | |||
| Period of return: | From: | 23 April 2019 | To: | 22 October 2019 |
| Balance under scheme from previous return: | 910,761 Ordinary Shares | |||
| The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: | N/A | |||
| Number of securities issued/allotted under scheme during period: | Nil | |||
| Balance under scheme not yet issued/allotted at end of period | 910,761 Ordinary Shares | |||
| Number and class of securities originally listed and the date of admission | 4,000,000 Ordinary Shares on 23 October 2013 | |||
| Total number of securities in issue at the end of the period | 654,990,841 Ordinary Shares | |||
| Name of contact: | Vred von Ketelhodt | |||
| Telephone number of contact: | 020 3637 4256 | |||
For further information, please contact:
| Ironveld plc Peter Cox, Chief Executive |
c/o Camarco 020 3757 4980 |
| finnCap | 020 7220 0500 |
| Christopher Raggett / Hannah Boros | |
| Camarco | 020 3757 4980 |
| Gordon Poole / Kimberley Taylor |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
BLRUASNRKOARUAA